Articles
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction
Mavacamten, per the VALOR-HCM trial, significantly reduced the long-term need for septal reduction therapy in severely symptomatic obstructive hypertrophic cardiomyopathy patients.
In severely symptomatic patients with obstructive hypertrophic cardiomyopathy (HCM), VALOR-HCM trial (Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [URL: https://clinicaltrials.gov; Unique identifier: NCT04349072]) reported that mavacamten reduced the short-term need for septal reduction therapy (SRT). The current report examined the longer-term effect of mavacamten through end of treatment at week 128.
Click here to access the article.